A blockbuster drug collapsing from $1,000 to $15 looks like a pricing story. It isn’t. It is a signal that control over human behavior, demand, and consumption is shifting fast. Between generics, new science, and AI-driven optimization, entire industries tied to addiction, food, and habit-driven spending may face structural decline. This episode breaks down why this disruption was inevitable and what happens next.

CHAPTERS

00:00 $1,000 drug drops to $15 overnight

00:30 The real story behind the price collapse

00:56 Patent cliff and global generics surge

01:40 Pricing pressure spreads beyond India

02:30 Who controls the pipeline

03:40 New research changes expectations

05:20 AI enters dosing and drug discovery

06:30 This becomes an economic story

07:00 Workforce and GDP implications

08:15 Spending shifts across industries

09:15 What breaks next

SOURCES

- Affordable GLP-1 Options Emerging in India and Beyond (CNBC): https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html

- Global Impact of Ozempic Generics Expanding to China and Canada (NYT): https://www.nytimes.com/2026/03/19/health/ozempic-wegovy-generic-india-china-canada.html

- Worldwide Reactions to Cheaper GLP-1 Drugs (BBC Analysis): https://www.bbc.com/news/articles/cx2g4411en3o

- AI Optimizing Weight Loss Outcomes: https://www.sciencedirect.com/science/article/abs/pii/S2405457725003821

- Personalized Semaglutide Therapy with Artificial Intelligence: https://ai.jmir.org/2026/1/e86960

- Breakthroughs in GLP-1 Drug Engineering: https://www.sciencedirect.com/science/article/pii/S1359644625000467

- Cutting-Edge Ozempic Alternatives in Research: https://www.nature.com/articles/s41586-025-08683-y

- Stanford Research on New Ozempic Rivals: https://med.stanford.edu/news/all-news/2025/03/ozempic-rival.html

- GLP-1 Demand and Consumer Purchase Data (Numerator Report): https://www.numerator.com/press/numerator-glp-1-hub-reveals-purchase-trends-from-30k-consumers/

- Marketing Shifts in the Weight-Loss Drug Space: https://journals.sagepub.com/doi/10.1177/00222437251412834

- Ozempic Frenzy: What’s Coming Next in Weight-Loss Drugs (WSJ): https://www.wsj.com/health/pharma/weight-loss-drug-frenzy-whats-here-and-whats-likely-coming-next-a84ef28b?mod=hp_lead_pos7

- GLP-1 Market Expansion Across Global Economies: https://www.arabnews.com/node/2637254/world

- New Findings on Stopping Ozempic and Mounjaro Use (Science Daily): https://www.sciencedaily.com/releases/2026/03/260319044648.htm#:~:text=03/260319044648.htm

- GLP-1 Insights from Griffith University Study (Science Daily): https://www.sciencedaily.com/releases/2026/03/260322020250.htm

FOLLOW GOOD REVENUE

• YouTube: https://www.youtube.com/channel/UCHrhuWbpYnUwrR75H2Ip4yQ 
• Spotify: https://open.spotify.com/show/44me6PABSQ0k0GfphM70au
• Apple Podcast: https://podcasts.apple.com/us/podcast/good-revenue/id1707461473 

Hosted on Acast. See acast.com/privacy for more information.